453 related articles for article (PubMed ID: 32877911)
21. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(10):611-621. PubMed ID: 34139691
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
[TBL] [Abstract][Full Text] [Related]
25. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
[TBL] [Abstract][Full Text] [Related]
27. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
32. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
[TBL] [Abstract][Full Text] [Related]
33. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
[TBL] [Abstract][Full Text] [Related]
34. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Yamauchi M; Ono A; Ishikawa A; Kodama K; Uchikawa S; Hatooka H; Zhang P; Teraoka Y; Morio K; Fujino H; Nakahara T; Murakami E; Miki D; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Hayes CN; Fujita M; Nakagawa H; Yasui W; Aikata H; Chayama K
Clin Transl Gastroenterol; 2020 May; 11(5):e00179. PubMed ID: 32677805
[TBL] [Abstract][Full Text] [Related]
35. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.
Shigesawa T; Suda G; Kimura M; Maehara O; Tokuchi Y; Kubo A; Yamada R; Furuya K; Baba M; Kitagataya T; Suzuki K; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
PLoS One; 2021; 16(3):e0247728. PubMed ID: 33647018
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
[TBL] [Abstract][Full Text] [Related]
37. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
39. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.
Zhu J; Fang P; Wang C; Gu M; Pan B; Guo W; Yang X; Wang B
Cancer Med; 2021 Nov; 10(22):7977-7987. PubMed ID: 34605616
[TBL] [Abstract][Full Text] [Related]
40. Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Matsuzaki T; Hashimoto S; Ohba K; Kugiyama Y; Yatsuhashi H; Shibata H; Motoyoshi Y; Shigeno M; Iwatsu S; Kato Y; Kinoshita N; Nakao K
Anticancer Res; 2021 Apr; 41(4):2025-2032. PubMed ID: 33813409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
